Table 2 Univariate analysis and multivariate analysis of the factors associated with OS

Age, years (≤ 78 vs. > 78)

0.011^#

0.51(0.300-0.858)

0.102

0.63(0.357–1.098)

Sex (male vs. female)

0.060

0.46(0.209–1.032)

0.001^#

0.35(0.182–0.660)

ECOG score (0–1 vs. 2)

0.453

0.64(0.200-2.052)

-

-

Tumor length, cm (< 5 vs. ≥ 5)

0.468

0.79(0.419–1.492)

-

-

Clinical stage (II vs. III)

0.946

0.98(0.569–1.694)

-

-

Clinical stage (II vs. IV)

0.932

0.98(0.670–1.444)

-

-

T stage (T1-2 vs. T3-4)

0.700

0.91(0.543–1.507)

-

-

N stage (N0-1 vs. N2-3)

0.074

0.35(0.108–1.108)

0.084

0.35(0.108–1.151)

Treatment discontinuation (no vs. yes)

0.500

0.71(0.255–1.947)

-

-

ALCmix, *10⁹/L (≤ 0.51 vs. > 0.51)

0.023^#

0.42(0.799–0.887)

0.034^#

0.44(0.207–0.941)

Heart V30, % (≤ 38.01 vs. > 38.01)

0.013^#

0.42(0.211–0.830)

0.006^#

0.34(0.158–0.735)

MHD, Gy (≤ 13.04 vs. > 13.04)

0.805

0.93(0.531–1.635)

-

-

Lung V5, % (≤ 45.89 vs. > 45.89)

0.511

0.83(0.473–1.452)

-

-

Lung V20, % (≤ 26.46 vs. > 26.46)

0.040^#

0.45(0.214–0.966)

0.019^#

0.39(0.179–0.858)

MLD, Gy (≤ 13.04 vs. > 13.04)

0.062

0.56(0.300-1.031)

0.139

0.61(0.320–1.173)